MedPath

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients

Not Applicable
Terminated
Conditions
Cachexia
Cancer
Interventions
Dietary Supplement: oral nutritional supplement, food for special medical purposes
Registration Number
NCT00851448
Lead Sponsor
Fresenius Kabi
Brief Summary

To test the compliance, tolerance, safety and to get preliminary insights into the efficacy of a new oral nutritional supplement (containing n-3 fatty acids, amino acids and antioxidants) designed to prevent or delay cachexia and anorexia in lung cancer patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • non-small cell lung cancer patients stage IIIb or IV
  • planned chemotherapy or combined chemo-/radiotherapy
  • current body weight less than 6 months ago
  • abnormal CRF level
  • BMI >=20 kg/m2 and <=30kg/m2
Exclusion Criteria
  • significant oedema in the time of screening and randomisation
  • concomitant inflammatory diseases
  • active infections including HIV and AIDS
  • liver failure
  • chronic renal failure or cardiac pacemaker
  • chronic heart failure
  • insulin treated diabetes mellitus
  • medications that impair sex hormone synthesis, secretion or function
  • acute or chronic infections
  • body weight loss > 5% during the last 6 months or > 10% during the last 10 months
  • fish oil supplementation within 3 months prior to study entry
  • taking vitamins in doses greater than recommended daily allowance
  • life expectancy less than 6 months in the opinion of the investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1oral nutritional supplement, food for special medical purposesOral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
2oral nutritional supplement, food for special medical purposesisocaloric, isonitrogenous
Primary Outcome Measures
NameTimeMethod
compliance to nutrition therapybaseline, months 1, 2, 3, 4
Secondary Outcome Measures
NameTimeMethod
ECOG performance statusbaseline, months 1, 2, 3, 4
anorexia questionnairebaseline, months 1, 2, 3, 4
gastrointestinal syndrome score (GIS)baseline, months 1, 2, 3, 4
body cell massbaseline, months 1, 2, 3, 4
weight changebaseline, months 1, 2, 3, 4
hand grip strengthbaseline, months 1, 2, 3, 4

Trial Locations

Locations (3)

Pulmonology Dept. of Miedzylesie Hospital

🇵🇱

Warsaw, Poland

Dipartimento di Medicina Clinica, La Sapienza Università, Rome

🇮🇹

Rome, Italy

Indywidualna Specjalistyczna Praktyka lekarska

🇵🇱

Ruda Slaska, Poland

© Copyright 2025. All Rights Reserved by MedPath